OBIO Orchestra BioMed Holdings, Inc. stock chart & analysis

Conviction 54HealthcareScan · Fri, Nov 6, 2026

Orchestra BioMed Holdings, Inc. (OBIO) closed at $5.68 (+1.07%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 49, RS Rating 94, -12.6% from its 52-week high, +36.9% year to date. Sector: Healthcare · Surgical & Medical Instruments & Apparatus.

OBIO$5.68+1.07%

ResistanceSupportVol 14Insider buyInsider sell

Loading chart…

Orchestra BioMed Holdings, Inc.Surgical & Medical Instruments & Apparatuswww.orchestrabiomed.com ↗

Price5.68

Change+1.07%

Gap-8.45%

Rel volume7.75×

Avg volume454.74K

Avg $ vol2.6M

SMA 205.73

SMA 505.74

SMA 2004.57

Price vs 50-1.11%

Price vs 200+24.19%

MA stackmixed

50/200 cross—

Supertrendup · 5.36

RSI (14)49

MACD hist-0.01

MACD crossbear · 1d

Stoch %K / %D52 / 53

ADX (14)13

+DI / −DI16 / 26

RSI divergence—

MACD divergence—

ATR %6.94%

ADR %6.39%

52w high6.50

52w low3.46

From 52w high-12.62%

Above 52w low+64.16%

New 52w highNo

SqueezeOn · 8d

Bollinger width12.17%

%B0.42

Donchian pos52.20%

Donchian high6.17

Donchian low5.15

AVWAP (52w high)5.76

vs AVWAP high-1.47%

AVWAP (52w low)4.75

vs AVWAP low+19.67%

OBV trendUp

Chaikin MF (20)-0.01

Today vs 20d7.75×

Avg vol (14d)533.96K

Avg vol (20d)454.74K

Avg $ vol (20d)2.6M

Market cap341.4M

RS Rating94 / 99

RS 3m (vs SPY)+32.22%

RS 6m (vs SPY)+40.90%

RS line new highNo

Trend template7/8

Technical rank80.1

1 week-3.89%

1 month-0.87%

3 months+27.35%

6 months+40.59%

1 year+44.90%

YTD+36.87%

P/E-6.48

P/B17.67

P/S10.20

P/FCF-6.90

EPS-1.11

Div yield—

ROE-272.74%

ROA-45.55%

Debt/Eq0.78

Current8.26

EV/EBITDA-6.53

Gross margin99.43%

Net margin-157.40%

Rev growth1169.22%

EPS growth13.64%

Price target—

Target upside—

Analyst rating—

Institutional46.66%

Ent. value335.92M

Revenue88K

Net income-23.75M

Gross profit63K

Free cash flow-49.45M

IndustrySurgical & Medical Instruments & Apparatus

ExchangeNasdaq

Shares out59.88M

Employees86

ListedFri, Jan 27, 2023

Free float29.71M

Float %49.6%

Short interest—

Days to cover—

Short volume69.5%

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction54 / 100

Pattern quality—

Tech rank80.1 / 100

Group rank23 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance6.49

Support5.38

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

OBIO technical analysis

Trend

OBIO's moving averages are mixed — no clean uptrend or downtrend. It closed 1.1% below the 50-day ($5.74) and 24.2% above the 200-day ($4.57). ADX(14) at 13 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.

Momentum

RSI(14) is 49, in the bearish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 94 puts its weighted 12-month performance ahead of about 94% of the US market.

Volume and volatility

Volume on the latest session ran 7.8× its 20-day average. It trades about $2.6M a day on average. ATR(14) is $0.3942, 6.9% of price — its typical daily range. Bollinger Bands are in a squeeze (8 sessions) — volatility is compressed. On-balance volume is trending up.

Key levels

The chart pattern's support is $5.38 and its resistance $6.49. The 52-week range is $3.46 to $6.50; price is 12.6% below the high and 64.2% above the low. The VWAP anchored at the 52-week high is $5.76, above price.

Performance

OBIO returned -3.9% (1 week), -0.9% (1 month), +27.4% (3 months), +40.6% (6 months), +44.9% (1 year), +36.9% (year to date).

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Surgical & Medical Instruments & Apparatus · Listed 2023 · 86 employees

Insider activity

SEC Form 4 transactions in OBIO · open-market 1 buy · 2 sells

Insider	Side	Shares	Value	Traded	Filed
Sherman Darren See Remarks · Common Stock, par value $0.0001 per share ("Common Stock") · 2026-11-02	Sell	15K	$86K	2026-11-02	2026-11-03
Hochman David P See Remarks · Common Stock · 2026-09-10	Tax	3.28K	$19K	2026-09-10	2026-09-11
Hochman David P See Remarks · Common Stock, par value $0.0001 per share ("Common Stock") · 2026-09-10	Tax	3.28K	$19K	2026-09-10	2026-09-11
Sherman Darren See Remarks · Common Stock, par value $0.0001 per share ("Common Stock") · 2026-09-01	Sell	15K	$74K	2026-09-01	2026-09-02
Aiello Joshua Principal Accounting Officer · Common Stock, par value $0.0001 per share · 2026-08-26	Tax	203	$1K	2026-08-26	2026-08-28
Sherman Darren See Remarks · Common Stock, par value $0.0001 per share ("Common Stock") · 2026-08-26	Tax	4.92K	$26K	2026-08-26	2026-08-28
Sherman Darren See Remarks · Common Stock · 2026-08-26	Buy	2K	$11K	2026-08-26	2026-08-28
Taylor Andrew Lawrence Chief Financial Officer · Common Stock, par value $0.0001 per share · 2026-08-26	Tax	3.08K	$16K	2026-08-26	2026-08-28
Cleary Chris Director · Common Stock, par value $0.0001 per share · 2026-08-12	Tax	4.24K	$19K	2026-08-12	2026-08-14
Fain Eric S Director · Common Stock, par value $0.0001 per share · 2026-08-12	Tax	5.14K	$23K	2026-08-12	2026-08-14

SEC filings

EDGAR filings in OBIO · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.